ERBB2 and breast carcinoma: In this context, especially the identification of patients with ER-positive HER2-negative breast cancer with intermediate or high risk of recurrence defined by conventional clinicopathological features but low risk defined by multigene assays seems to be important for therapy decisions regarding chemotherapy and endocrine therapy.